Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alassane Dicko

Showing results (151-160 of 163) with videos related to

Pageof 17
Sort By:
The New England Journal of Medicine|August 25, 2021
Seasonal Malaria Vaccination with or without Seasonal Malaria ChemopreventionDaniel Chandramohan, Issaka Zongo, Issaka Sagara, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2021
The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria VaccineIssaka Sagara, Issaka Zongo, Matthew Cairns, et al.
Lancet (London, England)|February 4, 2024
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S Datoo, Alassane Dicko, Halidou Tinto, et al.
The Lancet. Infectious Diseases|November 26, 2015
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trialIssaka Sagara, Abdoul Habib Beavogui, Issaka Zongo, et al.
The Lancet. Infectious Diseases|February 11, 2024
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling studyNora Schmit, Hillary M Topazian, H Magloire Natama, et al.
The Lancet. Infectious Diseases|November 3, 2022
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance studyKhalid B Beshir, Julian Muwanguzi, Johanna Nader, et al.
The Lancet. Infectious Diseases|August 17, 2024
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trialsHalimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, et al.
NPJ Vaccines|February 6, 2025
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01<sub>E</sub>M Sanni Ali, Lisa Stockdale, Issaka Sagara, et al.
The Lancet. Infectious Diseases|August 25, 2023
Seasonal vaccination with RTS,S/AS01<sub>E</sub> vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trialAlassane Dicko, Jean-Bosco Ouedraogo, Issaka Zongo, et al.
Plos One|January 24, 2008
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
Pageof 17

Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
The New England Journal of Medicine|August 25, 2021
Seasonal Malaria Vaccination with or without Seasonal Malaria ChemopreventionDaniel Chandramohan, Issaka Zongo, Issaka Sagara, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2021
The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria VaccineIssaka Sagara, Issaka Zongo, Matthew Cairns, et al.
Lancet (London, England)|February 4, 2024
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S Datoo, Alassane Dicko, Halidou Tinto, et al.
The Lancet. Infectious Diseases|November 26, 2015
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trialIssaka Sagara, Abdoul Habib Beavogui, Issaka Zongo, et al.
The Lancet. Infectious Diseases|February 11, 2024
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling studyNora Schmit, Hillary M Topazian, H Magloire Natama, et al.
The Lancet. Infectious Diseases|November 3, 2022
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance studyKhalid B Beshir, Julian Muwanguzi, Johanna Nader, et al.
The Lancet. Infectious Diseases|August 17, 2024
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trialsHalimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, et al.
NPJ Vaccines|February 6, 2025
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01<sub>E</sub>M Sanni Ali, Lisa Stockdale, Issaka Sagara, et al.
The Lancet. Infectious Diseases|August 25, 2023
Seasonal vaccination with RTS,S/AS01<sub>E</sub> vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trialAlassane Dicko, Jean-Bosco Ouedraogo, Issaka Zongo, et al.
Plos One|January 24, 2008
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
Pageof 17